ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1
Authors
Keywords
-
Journal
Future Oncology
Volume 16, Issue 15, Pages 991-999
Publisher
Future Medicine Ltd
Online
2020-04-06
DOI
10.2217/fon-2020-0176
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand
- (2017) Tanin Intragumtornchai et al. HEMATOLOGICAL ONCOLOGY
- ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
- (2016) Grzegorz S Nowakowski et al. Future Oncology
- State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma
- (2016) Annalisa Chiappella et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- (2016) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma
- (2016) Xueying Li et al. Oncotarget
- A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
- (2015) John D. Hainsworth et al. LEUKEMIA & LYMPHOMA
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
- (2015) Rosalba Camicia et al. Molecular Cancer
- A central role for TRPS1 in the control of cell cycle and cancer development
- (2015) Lele Wu et al. Oncotarget
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
- (2014) Laurie H. Sehn et al. BLOOD
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2014) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer
- (2013) J. Q. Chen et al. ANNALS OF ONCOLOGY
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- (2013) Z. Zhou et al. BLOOD
- Diffuse large B cell lymphoma: molecular targeted therapy
- (2012) Mark Roschewski et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
- (2011) Teri N. Kreisl et al. NEURO-ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started